Neoleukin Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>NT</div>
NLTX -- USA Stock  

USD 13.34  0.34  2.62%

Whilst many millenniums are getting more into healthcare space, it makes sense to break down Neoleukin Therapeutics against current trends within the economy. As expected, Neoleukin Therapeutics is starting to reaffirm its true potential as investors are becoming more and more confident in the future outlook. The returns on investing in Neoleukin Therapeutics and the market returns of the last few months appear uncorrelated. The appearance of strong technical and fundamental indicators of the company suggests a short-term price swing for investors of Neoleukin. The next fiscal quarter end is expected on the 31st of December 2020. The stock experiences an active upward rally.
Published over three weeks ago
View all stories for Neoleukin Therapeutics | View All Stories
Our current technical analysis of Neoleukin Therapeutics (NASDAQ:NLTX)
Neoleukin Therapeutics's average rating is Strong Buy from 7 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Neoleukin Therapeutics market sentiment investors' perception of the future value of Neoleukin. Let us look at a few aspects of Neoleukin technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Neoleukin Therapeutics. In general, we focus on analyzing Neoleukin Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Neoleukin Therapeutics's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Neoleukin Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for Neoleukin Therapeutics, we also check how macroeconomic factors affect Neoleukin Therapeutics price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Neoleukin Therapeutics' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Neoleukin Therapeutics in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Neoleukin Therapeutics. Your research has to be compared to or analyzed against Neoleukin Therapeutics' peers to derive any actionable benefits. When done correctly, Neoleukin Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Neoleukin Therapeutics.

How does Neoleukin Stands against Peers?

Analyzing Neoleukin Therapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Neoleukin Therapeutics across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Neoleukin Therapeutics Competition Details

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Neoleukin Therapeutics, but it might be worth checking our own buy vs. sell analysis

Purchase by Baker Bros Advisors Lp of 518555 shares of Neoleukin Therapeutics

Legal trades by Neoleukin Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Neoleukin insider trading alert for perchase of pre-funded warrants by Baker Bros Advisors Lp, the corporate stakeholder, on 23rd of December 2020. This event was filed by Neoleukin Therapeutics In with SEC on 2020-12-23. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Neoleukin Therapeutics Investor Appetite?

This firm has a beta of 0.1427. Let's try to break down what Neoleukin's beta means in this case. Neoleukin Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Neoleukin Therapeutics is expected to follow. The beta indicator helps investors understand whether Neoleukin Therapeutics moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Neoleukin deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The company reported the previous year's revenue of 22.37 M. Net Loss for the year was (28.74 M) with profit before overhead, payroll, taxes, and interest of 25 M.

Our take on today Neoleukin Therapeutics rise

Variance is down to 13.81. It may suggest a possible volatility slide. Neoleukin Therapeutics exhibits very low volatility with skewness of -0.22 and kurtosis of -0.58. However, we advise investors to further study Neoleukin Therapeutics technical indicators to make sure all market info is available and is reliable.

Our Final Takeaway

While many of the other players under the drug manufacturers?specialty & generic industry are still a bit expensive, Neoleukin Therapeutics may offer a potential longer-term growth to investors. While some investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Neoleukin Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Neoleukin Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com